These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 29139346)

  • 1.
    Nykvist M; Gillman A; Söderström Lindström H; Tang C; Fedorova G; Lundkvist Å; Latorre-Margalef N; Wille M; Järhult JD
    J Gen Virol; 2017 Dec; 98(12):2937-2949. PubMed ID: 29139346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
    Tepper V; Nykvist M; Gillman A; Skog E; Wille M; Lindström HS; Tang C; Lindberg RH; Lundkvist Å; Järhult JD
    J Gen Virol; 2020 Aug; 101(8):816-824. PubMed ID: 31855133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Environmental resistance development to influenza antivirals: a case exemplifying the need for a multidisciplinary One Health approach including physicians.
    Järhult JD
    Acta Vet Scand; 2018 Jan; 60(1):6. PubMed ID: 29370857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.
    Gillman A; Nykvist M; Muradrasoli S; Söderström H; Wille M; Daggfeldt A; Bröjer C; Waldenström J; Olsen B; Järhult JD
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5196-202. PubMed ID: 26077257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oseltamivir Resistance in Influenza A(H6N2) Caused by an R292K Substitution in Neuraminidase Is Not Maintained in Mallards without Drug Pressure.
    Gillman A; Muradrasoli S; Mårdnäs A; Söderström H; Fedorova G; Löwenthal M; Wille M; Daggfeldt A; Järhult JD
    PLoS One; 2015; 10(9):e0139415. PubMed ID: 26422258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
    Nguyen HT; Trujillo AA; Sheu TG; Levine M; Mishin VP; Shaw M; Ades EW; Klimov AI; Fry AM; Gubareva LV
    Antiviral Res; 2012 Mar; 93(3):381-6. PubMed ID: 22330888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.
    Kossyvakis A; Mentis AA; Tryfinopoulou K; Pogka V; Kalliaropoulos A; Antalis E; Lytras T; Meijer A; Tsiodras S; Karakitsos P; Mentis AF
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):361-371. PubMed ID: 27848039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.
    Burnham AJ; Armstrong J; Lowen AC; Webster RG; Govorkova EA
    J Virol; 2015 Apr; 89(8):4575-87. PubMed ID: 25673705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
    Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
    J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long time scale GPU dynamics reveal the mechanism of drug resistance of the dual mutant I223R/H275Y neuraminidase from H1N1-2009 influenza virus.
    Woods CJ; Malaisree M; Pattarapongdilok N; Sompornpisut P; Hannongbua S; Mulholland AJ
    Biochemistry; 2012 May; 51(21):4364-75. PubMed ID: 22574858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Susceptibility of human influenza A (H3N2) viruses to neuraminidase inhibitors isolated during 2011-2012 in China].
    Huang W; Tan M; Zhao X; Cheng Y; Li X; Guo J; Wei H; Xiao N; Wang Z; Wang D; Shu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Jun; 49(6):481-4. PubMed ID: 26310330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
    McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
    J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
    Kode SS; Pawar SD; Tare DS; Keng SS; Hurt AC; Mullick J
    Vet Microbiol; 2019 Aug; 235():21-24. PubMed ID: 31282375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
    Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.